8-K: LifeVantage Reports Mixed Q3 Results: Revenue Declines but Profitability Improves

LifeVantage Corporation reported a decrease in revenue for the third quarter of fiscal year 2024, but saw significant improvements in profitability and adjusted EBITDA.

Summary

• LifeVantage Corporation announced its financial results for the third quarter of fiscal year 2024, which ended March 31, 2024.
• The company's revenue was $48.2 million, a 10.2% decrease compared to the same period last year, or an 8.7% decrease excluding foreign currency impacts.
• Revenue in the Americas decreased by 5.9%, while revenue in Asia/Pacific & Europe decreased by 22.4%, or 16.1% on a constant currency basis.
• Net income per diluted share was $0.13, up from $0.08 per diluted share in the prior year.
• Adjusted earnings per diluted share was $0.21, compared to $0.08 a year ago.
• Adjusted EBITDA increased by 54.7% to $5.1 million.
• The company generated $9.6 million in cash from operations during the first nine months of fiscal 2024, compared to $3.1 million in the same period last year.
• LifeVantage repurchased 0.3 million shares of its common stock for $1.9 million during the quarter.
• The company declared a cash dividend of $0.04 per common share, payable on June 14, 2024.
• Fiscal year 2024 revenue guidance was revised to $202 million to $205 million, down from the previous range of $207 million to $213 million, while adjusted EBITDA guidance remains unchanged at $16 million to $18 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While profitability metrics improved significantly, the revenue decline and lowered guidance are concerning. The company is showing progress in its transformation plan, but it still faces challenges.

Positives

• Adjusted EBITDA saw a significant increase of 54.7% to $5.1 million.
• Adjusted EBITDA margin reached double digits at 10.5% for the first time in 10 quarters.
• Net income per diluted share increased to $0.13 from $0.08 year-over-year.
• Adjusted earnings per diluted share increased to $0.21 from $0.08 year-over-year.
• Cash from operations improved to $9.6 million for the first nine months of fiscal 2024, compared to $3.1 million in the same period last year.
• Revenue per consultant increased by 6% despite a 15% gain in the prior year.
• The company declared a cash dividend of $0.04 per common share.

Negatives

• Revenue decreased by 10.2% year-over-year to $48.2 million.
• Revenue in the Americas decreased by 5.9%.
• Revenue in Asia/Pacific & Europe decreased by 22.4%, or 16.1% on a constant currency basis.
• Gross profit margin decreased to 78.9% from 80.2% due to product mix, raw material costs, and shipping expenses.
• The company revised its full-year revenue guidance down to $202 million to $205 million from $207 million to $213 million.

Risks

• The company faces challenges in the operating environment, particularly on the top line.
• There is a risk of further deterioration in the global economic and operating environments due to future COVID-19 developments.
• The company's actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• The company's revenue is declining in both the Americas and Asia/Pacific & Europe regions.
• The company's gross profit margin has decreased due to various factors.

Future Outlook

The company expects to generate revenue in the range of $202 million to $205 million in fiscal year 2024 and adjusted EBITDA of $16 million to $18 million, with adjusted earnings per share in the range of $0.57 to $0.67. The company expects a full year tax rate of approximately 22% to 24%.

Management Comments

• Steve Fife, President and Chief Executive Officer of LifeVantage, stated that they were very pleased with their improved profitability in the third quarter, reflecting continued progress with their LV360 strategic transformation.
• Management noted that productivity gains have helped drive operating margins and mitigate top-line headwinds.
• Management also noted that revenue per Consultant continued to trend upward, rising 6% in the third quarter despite cycling a 15% gain a year earlier.
• Management stated that recent Momentum Academy events have been well attended and they continue to see high levels of engagement along with very positive responses to their latest products and innovation.
• Management expressed confidence in their ability to drive long-term value for stockholders as their LV360 transformation plan continues to gain traction.

Industry Context

LifeVantage operates in the health and wellness industry, which is experiencing both growth and challenges. The company's direct selling model is facing headwinds, as evidenced by the decline in revenue. However, the company's focus on nutrigenomics and its strategic transformation plan may provide a competitive advantage. The company's performance is being impacted by global economic conditions and foreign currency fluctuations, which are affecting many companies in the industry.

Comparison to Industry Standards

• LifeVantage's revenue decline of 10.2% is worse than some of its competitors in the health and wellness space, many of whom are experiencing growth or smaller declines.
• Companies like Herbalife and Nu Skin have reported mixed results, with some regions showing growth while others decline, similar to LifeVantage's regional performance.
• The increase in LifeVantage's adjusted EBITDA by 54.7% is a positive sign, indicating improved operational efficiency, which is a key metric for investors in the direct selling industry.
• The company's adjusted EBITDA margin of 10.5% is a positive step, but it is still below the industry average for some established players.
• LifeVantage's focus on nutrigenomics is a differentiator, but it needs to translate into revenue growth to compete effectively with companies that have broader product portfolios and established customer bases.

Stakeholder Impact

• Shareholders will be impacted by the decreased revenue guidance, but may be encouraged by the improved profitability and dividend announcement.
• Employees may be affected by the ongoing strategic transformation and any potential restructuring.
• Customers may see changes in product offerings and pricing as the company continues to innovate.
• Suppliers may be impacted by changes in product mix and manufacturing costs.
• Creditors will be impacted by the company's financial performance and cash flow.

Next Steps

• The company will continue to execute its LV360 strategic transformation plan.
• The company will hold an investor conference call to discuss the results.
• The company will pay a cash dividend on June 14, 2024.

Key Dates

Keywords

LifeVantage, financial results, revenue, EBITDA, net income, earnings per share, direct selling, nutrigenomics, health and wellness, stock repurchase, dividend